The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer

被引:6
|
作者
Bragina, Olga D. [1 ,2 ]
Deyev, Sergei M. [2 ,3 ]
Chernov, Vladimir, I [1 ,2 ]
Tolmachev, Vladimir M. [2 ,4 ]
机构
[1] Russian Acad Sci, Canc Res Inst, Tomsk Natl Res Med Ctr, Tomsk 634009, Russia
[2] Natl Res Tomsk Polytech Univ, Tomsk 634050, Russia
[3] Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia
[4] Uppsala Univ, Uppsala, Sweden
来源
ACTA NATURAE | 2022年 / 14卷 / 02期
关键词
breast cancer; HER2/neu; radionuclide diagnostics; monoclonal antibody; alternative scaffold proteins; HER2; EXPRESSION; THERAPEUTIC TARGETS; RECEPTOR; THERANOSTICS; TRASTUZUMAB; DISCORDANCE; CONCORDANCE; METASTASES; BIOMARKERS; GUIDELINES;
D O I
10.32607/actanaturae.11611
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This review examines the evolution of the radionuclide diagnosis of HER2-positive breast cancer using various compounds as a targeting module in clinical practice: from full-length antibodies to a new group of small synthetic proteins called alternative scaffold proteins. This topic is of especial relevance today in view of the problems attendant to the detection of breast cancer with HER2/neu overexpression, which, in most cases, introduce errors in the treatment of patients. The results of clinical studies of radiopharmaceuticals based on affibody molecules, ADAPTs, and DARPins for SPECT and PET have demonstrated good tolerability of the compounds, their rapid excretion from the body, and the possibility to differentiate tumor sites depending on the HER2/neu status. This indicates that targeted radionuclide diagnosis holds promise and the need to continue research in this direction.
引用
收藏
页码:4 / 15
页数:12
相关论文
共 50 条
  • [21] Pertuzumab: A New Targeted Therapy for HER2-Positive Metastatic Breast Cancer
    Malenfant, Stephanie J.
    Eckmann, Karen R.
    Barnett, Chad M.
    PHARMACOTHERAPY, 2014, 34 (01): : 60 - 71
  • [22] Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
    Hong, Joohyun
    Park, Yeon Hee
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [23] Pertuzumab in HER2-positive breast cancer
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (10) : 1709 - 1716
  • [24] Treatment of HER2-positive breast cancer
    Figueroa-Magalhaes, Maria Cristina
    Jelovac, Danijela
    Connolly, Roisin M.
    Wolff, Antonio C.
    BREAST, 2014, 23 (02): : 128 - 136
  • [25] Inflammatory HER2-positive breast cancer
    Dirix, Luc Y.
    Vermeulen, Peter B.
    LANCET ONCOLOGY, 2012, 13 (04): : 324 - 326
  • [26] Margetuximab for HER2-Positive Breast Cancer
    Cuellar, Sandra
    ONCOLOGY-NEW YORK, 2021, 35 (09): : 573 - 575
  • [27] HER2-positive advanced breast cancer
    Robert, Nicholas J.
    Favret, Anne M.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 21 (02) : 293 - +
  • [28] Lapatinib in HER2-positive breast cancer
    Nelson, Roxanne
    LANCET ONCOLOGY, 2018, 19 (01): : 22 - 22
  • [29] Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
    Yang, Xiaojing
    Ren, Hanru
    Xu, Yi
    Peng, Xue
    Yu, Wenxi
    Shen, Zan
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2023, 28 (01)
  • [30] The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer
    Dieras, Veronique
    Bachelot, Thomas
    TARGETED ONCOLOGY, 2014, 9 (02) : 111 - 122